logo-loader
viewMereo BioPharma Group PLC

Mereo BioPharma CEO confident as it moves forward with pivotal Setrusumab study

Mereo BioPharma's (LON:MPH) Denise Scots-Knight explains why she's confident in the potential of their lead drug setrusumab despite it not meeting its primary endpoint in a recent Phase 2b study.

The drug's being developed as a treatment for osteogenesis imperfecta which is also known as brittle bone disease.

Quick facts: Mereo BioPharma Group PLC

Price: 28 GBX

AIM:MPH
Market: AIM
Market Cap: £27.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Ontario's cannabis retail expansion plan gives cannabis stocks...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was 1.4% higher at 116.7 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF jumped 2.4% at C$9.55, while the OTCQX Cannabis index gained 0.6% to 434 points. Buds today are The Green...

1 day, 22 hours ago

RNS

PDMR Shareholding

1 week, 5 days ago

Director Shareholding

2 weeks, 4 days ago

Director Shareholding

2 weeks, 6 days ago

Director/PDMR Shareholding

3 weeks, 2 days ago

PDMR Shareholding

3 weeks, 4 days ago

2 min read